

### General information about company

Scrip code	000000	
NSE Symbol	BALAXI	
MSEI Symbol	NOTLISTED	
ISIN	INE618N01022	
Name of the entity	BALAXI PHARMACEUTICALS LIMITED	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Reporting Quarter Type	Yearly	
Date of Quarter Ending	31-03-2026	
Type of company	Equity	
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	Yes	
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes	
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	No	During the quarter under review, there were no instances of acquisition of shares or voting rights in unlisted companies by the Company.
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	No	There were no such instances during the quarter under review.
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	No	There were no such instances during the quarter under review.
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans /	No	The Company has not given any loans /guarantees / comfort letters / securities etc. to the Promoters / Promoter Group / Directors / KMPs or

Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?	any other entity controlled by the Promoters / Promoter Group / Directors/ KMPs.
Risk management committee	Applicable
Market Capitalisation as per immediate previous Financial Year	Top 2000 listed entities
Is SCORE ID Available ?	Yes
SCORE Registration ID	a00630
Reason For No SCORE ID	
Type of Submission	Original
Remarks (website dissemination)	
Remarks for Exchange (not for Website Dissemination)	

## Annexure I

### Annexure I to be submitted by listed entity on quarterly basis

#### I. Composition of Board of Directors

Disclosure of notes on composition of board of directors explanatory

Whether the listed entity has a Regular Chairperson

Yes

Whether Chairperson is related to MD or CEO

Yes

Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth
1	Mr	ASHISH MAHESHWARI	ADKPM6911H	01575984	Executive Director	Chairperson	MD	20-04-1970
2	Mrs	MINOSHI MAHESHWARI	ADGPM5813J	01575975	Non-Executive - Non Independent Director	Not Applicable		08-07-1972
3	Mr	KUNAL MAHENDRA BHAKTA	AFFPB8612K	01710557	Non-Executive - Independent Director	Not Applicable		10-01-1982
4	Mr	GANDHI GAMJI	AOLPG5480R	01944694	Non-Executive - Independent Director	Not Applicable		12-10-1969
5	Mr	MANGINA SRINIVAS RAO	ACHPR6536R	08095079	Non-Executive - Independent Director	Not Applicable		09-08-1960
6	Ms	AKSHITA SURANA	DMGPS7960N	10026552	Non-Executive - Independent Director	Not Applicable		17-08-1990

**I. Composition of Board of Directors**

**Disqualification of Directors under section 164 of the Companies Act, 2013**

Sr	Whether the director is disqualified?	Start Date of disqualification	End Date of disqualification	Details of disqualification	Current status
1	No				Active
2	No				Active
3	No				Active
4	No				Active
5	No				Active
6	No				Active

### I. Composition of Board of Directors

Sr	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity [with reference to proviso to regulation 17A(1) & reg. 17A(2)]	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	Notes for not providing PAN	Notes for not providing DIN
1	NA		04-05-2017	03-05-2022			1	0	1	0			
2	NA		12-02-2018	25-08-2025			1	0	1	0			
3	NA		04-05-2017	04-05-2022		106.28	1	1	2	2			
4	NA		04-05-2017	04-05-2022		106.28	1	1	2	0			
5	NA		15-09-2020	15-09-2023		66.17	7	7	10	3			
6	NA		05-09-2024			18.27	1	1	0	0			

Audit Committee Details							
Whether the Audit Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01710557	KUNAL MAHENDRA BHAKTA	Non-Executive - Independent Director	Chairperson	04-05-2017		
2	01944694	GANDHI GAMJI	Non-Executive - Independent Director	Member	04-05-2017		
3	01575984	ASHISH MAHESHWARI	Executive Director	Member	04-05-2017		
4	08095079	MANGINA SRINIVAS RAO	Non-Executive - Independent Director	Member	01-02-2024		

<b>Nomination and remuneration committee</b>							
Whether the Nomination and remuneration committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01710557	KUNAL MAHENDRA BHAKTA	Non-Executive - Independent Director	Chairperson	04-05-2017		
2	01944694	GANDHI GAMJI	Non-Executive - Independent Director	Member	04-05-2017		
3	01575975	MINOSHI MAHESHWARI	Non-Executive - Non Independent Director	Member	12-02-2018		

Stakeholders Relationship Committee							
Whether the Stakeholders Relationship Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01710557	KUNAL MAHENDRA BHAKTA	Non-Executive - Independent Director	Chairperson	04-05-2017		
2	01944694	GANDHI GAMJI	Non-Executive - Independent Director	Member	04-05-2017		
3	01575975	MINOSHI MAHESHWARI	Non-Executive - Non Independent Director	Member	04-05-2017		

**Risk Management Committee**

Whether the Risk Management Committee has a Regular Chairperson							
					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01575984	ASHISH MAHESHWARI	Executive Director	Chairperson	20-05-2021		
2	01944694	GANDHI GAMJI	Non-Executive - Independent Director	Member	20-05-2021		
3	99999999	AMOL ANAND MANTRI	Chief Financial Officer	Member	20-05-2021		Textual Information(1)

**Sr Text Block**

Textual Information(1)

As Mr. Amol Anand Mantri is a Chief Financial Officer of the Company and not a Director, he does not have a DIN Number. NSE Circular on FAQs on the submission of the quarterly Corporate Governance Report clears that: "If DIN is not applicable, the Company needs to mention only the dummy DIN (99999999) along with the reason in company remarks." We are following the same.

<b>Corporate Social Responsibility Committee</b>							
Whether the Corporate Social Responsibility Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01575975	MINOSHI MAHESHWARI	Non-Executive - Non Independent Director	Chairperson	16-06-2020		
2	01575984	ASHISH MAHESHWARI	Executive Director	Member	16-06-2020		
3	01944694	GANDHI GAMJI	Non-Executive - Independent Director	Member	16-06-2020		

<b>Other Committee</b>						
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks

## Annexure 1

### Annexure 1

#### III. Meeting of Board of Directors

Disclosure of notes on meeting of board of directors explanatory				Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*
Sr. No.	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)					
1	11-11-2025				Yes	6	6	4
2		28-01-2026	77		Yes	6	6	4
3		25-03-2026	55		Yes	6	6	4

## Annexure 1

### IV. Meeting of Committees

Disclosure of notes on meeting of committees explanatory										
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
1	Audit Committee	11-11-2025				Yes	4	4	3	0
2	Audit Committee	28-01-2026	77			Yes	4	4	3	0
3	Nomination and remuneration committee	30-05-2025				Yes	3	3	2	0
4	Nomination and remuneration committee	28-01-2026	242			Yes	3	3	2	0
5	Nomination and remuneration committee	25-03-2026	55			Yes	3	3	2	0
6	Stakeholders Relationship Committee	10-02-2025				Yes	3	3	2	0

## Annexure 1

### IV. Meeting of Committees

Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
7	Stakeholders Relationship Committee	28-01-2026	351			Yes	3	3	2	0

## Annexure 1

### V. Affirmations

Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	Yes
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes

**Annexure 1**

Sr	Subject	Compliance status
1	Name of signatory	Aman Purohit
2	Designation	Company Secretary and Compliance Officer

**Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)**

**I. Disclosure on website in terms of LODR Regulation**

**Sr**

Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address
As per regulation 46(2) of the LODR:				
1.1	Details of business	Yes		<a href="https://balaxipharma.in/corporate-overview">https://balaxipharma.in/corporate-overview</a>
1.2	Memorandum of Association and Articles of Association	Yes		<a href="https://balaxipharma.in/assets/images/corporatepolicies/Memorandum_Articles_of_Association.pdf">https://balaxipharma.in/assets/images/corporatepolicies/Memorandum_Articles_of_Association.pdf</a>
1.3	Brief profile of board of directors including directorship and full-time positions in body corporates	Yes		<a href="https://balaxipharma.in/board-of-directors">https://balaxipharma.in/board-of-directors</a>
2	Terms and conditions of appointment of independent directors	Yes		<a href="https://balaxipharma.in/assets/images/corporatepolicies/TermsandConditionsforIDAppointment.pdf">https://balaxipharma.in/assets/images/corporatepolicies/TermsandConditionsforIDAppointment.pdf</a>

3	Composition of various committees of board of directors	Yes		<a href="https://balaxipharma.in/board-committees">https://balaxipharma.in/board-committees</a>
4	Code of conduct of board of directors and senior management personnel	Yes		<a href="https://balaxipharma.in/assets/images/corporatepolicies/Code_of_Conduct.pdf">https://balaxipharma.in/assets/images/corporatepolicies/Code_of_Conduct.pdf</a>
5	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		<a href="https://balaxipharma.in/assets/images/corporatepolicies/BPL_WHISTLE_BLOWER_POLICY.pdf">https://balaxipharma.in/assets/images/corporatepolicies/BPL_WHISTLE_BLOWER_POLICY.pdf</a>
6	Criteria of making payments to non-executive directors	Yes		<a href="https://balaxipharma.in/assets/images/corporatepolicies/Remuneration_Policy.pdf">https://balaxipharma.in/assets/images/corporatepolicies/Remuneration_Policy.pdf</a>
7	Policy on dealing with related party transactions	Yes		<a href="https://balaxipharma.in/assets/images/corporatepolicies/02-POLICY_ON_RELATED_PARTY_TRANSACTIONS.pdf">https://balaxipharma.in/assets/images/corporatepolicies/02-POLICY_ON_RELATED_PARTY_TRANSACTIONS.pdf</a>
8	Policy for determining 'material' subsidiaries	Yes		<a href="https://balaxipharma.in/assets/images/corporatepolicies/03-POLICY_ON_MATERIAL_SUBSIDIARY.pdf">https://balaxipharma.in/assets/images/corporatepolicies/03-POLICY_ON_MATERIAL_SUBSIDIARY.pdf</a>
9	Details of familiarization programmes imparted to independent directors	Yes		<a href="https://balaxipharma.in/assets/images/corporatepolicies/Familiarization_Programme.pdf">https://balaxipharma.in/assets/images/corporatepolicies/Familiarization_Programme.pdf</a>

10	Email address for grievance redressal and other relevant details	Yes		<a href="https://balaxipharma.in/investor-contacts">https://balaxipharma.in/investor-contacts</a>
11	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		<a href="https://balaxipharma.in/investor-contacts">https://balaxipharma.in/investor-contacts</a>
12	Financial results	Yes		<a href="https://balaxipharma.in/financial-results">https://balaxipharma.in/financial-results</a>
13	Shareholding pattern	Yes		<a href="https://balaxipharma.in/investor-shareholder-pattern">https://balaxipharma.in/investor-shareholder-pattern</a>
14	Details of agreements entered into with the media companies and/or their associates	NA		

**Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)**

**I. Disclosure on website in terms of LODR Regulation**

**Sr**

	As per regulation 46(2) of the LODR:		
15.1	(I) Schedule of analyst or institutional investor meet (II) Presentations prepared by the listed entity for analysts or institutional investors meet, post earnings or quarterly calls prior to beginning of such events.	Yes	<a href="https://balaxipharma.in/corporate-announcements">https://balaxipharma.in/corporate-announcements</a>
15.2	Audio recordings, video recordings, if any, and transcripts of post earnings or quarterly calls, by whatever name called, conducted physically or	Yes	<a href="https://balaxipharma.in/corporate-announcements">https://balaxipharma.in/corporate-announcements</a>

	through digital means		
16	New name and the old name of the listed entity	NA	
17	Advertisements as per regulation 47 (1)	Yes	<a href="https://balaxipharma.in/press-releases">https://balaxipharma.in/press-releases</a>
18	Credit rating or revision in credit rating obtained	Yes	<a href="https://balaxipharma.in/credit-rating">https://balaxipharma.in/credit-rating</a>
19	Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	Yes	<a href="https://balaxipharma.in/subsidiaries-financial-statements">https://balaxipharma.in/subsidiaries-financial-statements</a>
20	Secretarial Compliance Report	Yes	<a href="https://balaxipharma.in/corporate-announcements">https://balaxipharma.in/corporate-announcements</a>
21	Materiality Policy as per Regulation 30 (4)	Yes	<a href="https://balaxipharma.in/assets/images/corporatepolicies/POLICY_FOR_DETERMINING_MATERIAL_INFORMATION.pdf">https://balaxipharma.in/assets/images/corporatepolicies/POLICY_FOR_DETERMINING_MATERIAL_INFORMATION.pdf</a>
22	Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as	Yes	<a href="https://balaxipharma.in/assets/images/corporatepolicies/Contact_Details_of_KMPs_for_Determining_Materiality.pdf">https://balaxipharma.in/assets/images/corporatepolicies/Contact_Details_of_KMPs_for_Determining_Materiality.pdf</a>

	required under regulation 30(5)		
23	Disclosures under regulation 30(8)	Yes	<a href="https://balaxipharma.in/corporate-announcements">https://balaxipharma.in/corporate-announcements</a>
24	Statements of deviation(s) or variations(s) as specified in regulation 32	Yes	<a href="https://balaxipharma.in/corporate-announcements">https://balaxipharma.in/corporate-announcements</a>
25	Dividend Distribution policy as per Regulation 43A(1)	Yes	<a href="https://balaxipharma.in/assets/images/corporatepolicies/Dividend_Distribution_Policy.pdf">https://balaxipharma.in/assets/images/corporatepolicies/Dividend_Distribution_Policy.pdf</a>
26.1	Annual return as provided under section 92 of the Companies Act, 2013	Yes	<a href="https://balaxipharma.in/investor-annual-report">https://balaxipharma.in/investor-annual-report</a>
26.2	Employee Benefit scheme documents framed in terms of SEBI (SBEB) Regulations, 2021	NA	
27	Confirmation that the above disclosures are in a separate section as specified in	Yes	<a href="https://balaxipharma.in/disclosures-regulation">https://balaxipharma.in/disclosures-regulation</a>

	regulation 46(2)		
28	Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating	Yes	<a href="https://www.balaxipharma.in/">https://www.balaxipharma.in/</a>
Disclosure of notes on website in terms of Listing Regulations explanatory [Text Block]		Textual Information(1)	

**Text Block**

Textual Information(1)

Clarification Note for Point 26.1: Annual Return as provided under Section 92 of the Companies Act, 2013 can be accessed by selecting the 'Miscellaneous Tab' after visiting the web address:  
<https://balaxipharma.in/investor-annual-report>

## Annexure II

### II. Annual Affirmations

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
1	Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	16(1)(b)	Yes	
2	Board composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes	
3	Meeting of Board of directors	17(2)	Yes	
4	Quorum of Board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	Yes	
6	Plans for orderly succession for appointments	17(4)	Yes	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	Yes	
9	Minimum Information	17(7)	Yes	
10	Compliance Certificate	17(8)	Yes	

## Annexure II

### II. Annual Affirmations

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
11	Risk Assessment & Management	17(9)	Yes	
12	Performance Evaluation of Independent Directors	17(10)	Yes	
13	Recommendation of Board	17(11)	Yes	
14	Maximum number of Directorships	17A	Yes	
15	Composition of Audit Committee	18(1)	Yes	
16	Meeting of Audit Committee	18(2)	Yes	
17	Role of Audit Committee and information to be reviewed by the audit committee	18(3)	Yes	
18	Composition of nomination & remuneration committee	19(1) & (2)	Yes	
19	Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
20	Meeting of Nomination and Remuneration Committee	19(3A)	Yes	

## Annexure II

### II. Annual Affirmations

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.
21	Role of Nomination and Remuneration Committee	19(4)	Yes	
22	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes	
23	Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
24	Role of Stakeholders Relationship Committee	20(4)	Yes	
25	Composition and role of risk management committee	21(1),(2),(3),(4)	Yes	
26	Meeting of Risk Management Committee	21(3A)	Yes	
27	Quorum of Risk Management Committee meeting	21(3B)	Yes	
28	Gap between the meetings of the Risk Management Committee	21(3C)	Yes	
29	Vigil Mechanism	22	Yes	
30	Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes	

## Annexure II

### II. Annual Affirmations

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.
31	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
32	Approval for material related party transactions	23(4)	NA	
33	Disclosure of related party transactions on consolidated basis	23(9)	Yes	
34	Composition of Board of Directors of unlisted material Subsidiary	24(1)	Yes	
35	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4), (5) & (6)	Yes	
36	Alternate Director to Independent Director	25(1)	NA	
37	Maximum Tenure	25(2)	Yes	
38	Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	Yes	
39	Meeting of independent directors	25(3) & (4)	Yes	
40	Familiarization of independent directors	25(7)	Yes	

## Annexure II

### II. Annual Affirmations

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.
41	Declaration from Independent Director	25(8) & (9)	Yes	
42	Directors and Officers insurance	25(10)	Yes	
43	Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	Yes	
44	Memberships in Committees	26(1)	Yes	
45	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
46	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
47	Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	NA	
48	Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2), 26A(3)	Yes	
	Any other information to be provided - Add Notes			

**Annexure II**

1	Name of signatory	Aman Purohit
2	Designation	Company Secretary and Compliance Officer

## Annexure II

### III. Affirmations

Sr	Particulars	Compliance status (Yes/No/NA)
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	Yes
	Any other information to be provided	

**Annexure II**

<b>Annexure II</b>		
1	Name of signatory	Aman Purohit
2	Designation	Company Secretary and Compliance Officer

**Details of Cyber security incidence**

Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter

No

Number of cyber security incidence or breaches or loss of data event occurred during the quarter

Sr.

Date of the event

Brief details of  
the event

**Signatory Details**

Name of signatory	Aman Purohit
Designation of person	Company Secretary and Compliance Officer
Place	Hyderabad
Date	28-04-2026

**Investor Grievance Details**

No. of investor complaints pending at the beginning of Quarter	0
No. of investor complaints received during the Quarter	0
No. of investor complaints disposed off during the Quarter	0
No. of investor complaints those remaining unresolved at the end of the Quarter	0

